Drugs News and Research

RSS

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN).

15 Sep 2010

Mechanism linking brain activity to sleep discovered

Washington State University researchers have discovered the mechanism by which the brain switches from a wakeful to a sleeping state. The finding clears the way for a suite of discoveries, from sleeping aids to treatments for stroke and other brain injuries.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Elsevier today announces that it has significantly increased its service offering to pharmaceutical R&D professionals with the launch of a new Pharmacokinetics Module of PharmaPendium-, the online resource for authoritative drug development data.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Stroke risk with common pain killers dismissed by manufacturer

An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, “it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day.”

14 Sep 2010

Stemedica Cell Technologies completes master bank of mesenchymal bone marrow-derived stem cells

Stemedica Cell Technologies, Inc., a world leader in adult stem cell manufacturing and research, announced today that it has completed its proprietary master bank of mesenchymal bone marrow-derived stem cells.

14 Sep 2010

Absence of clean, sanitary drinking water a global concern

One of the biggest concerns facing Americans and people worldwide today is the absence of clean, sanitary drinking water. Over the past few years people have begun to wake up to the fact that their tap water isn't as clean as they originally thought; the discovery has been made that a large portion of drinking water in the United States is laced with pharmaceuticals and chemicals.

14 Sep 2010

AIDS activists protest to decry Obama administration's dismal record on AIDS

52 AIDS activists from the groups Housing Works, AIDS Action in Mississippi (AAIM) and AIDS Healthcare Foundation (AHF) interrupted a speech by Health and Human Services Secretary Kathleen Sebelius with a spirited protest to decry the Obama administration's dismal record on AIDS during an appearance by the Secretary at the United States Conference on AIDS (USCA) on Monday in Orlando.

14 Sep 2010

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Over a 1000 experts from the world will participate in the Osteoarthritis Research Society International (OARSI) congress, under the Presidency of the Belgian Professor Yves Henrotin (University of Liège).

14 Sep 2010

RNAO endorses 'The Economic Case for Universal Pharmacare'

Registered nurses from across Ontario are throwing their support behind detailed economic analysis in a report that concludes a national pharmacare program would improve equitable access to essential medicines, improve health outcomes and save Canadians up to $10.7 billion.

14 Sep 2010

Over half of men surveyed believe erectile dysfunction as a symptom of overall health

A new poll of men and women over 50 years old reveals that, while most men report some level of erectile dysfunction (ED), women generally aren't aware of the problem in their partners. The problem extends beyond simple communication since ED can often be a symptom of overall health and well-being in men.

14 Sep 2010

SAMHSA to unveil results of 2009 National Survey on Drug Use and Health

The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.

14 Sep 2010

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

The Academy of Managed Care Pharmacy (AMCP) supports the inclusion of legislative language similar to S. 369 — the Preserve Access to Affordable Generics Act — in appropriations legislation now under consideration by the Senate. S. 369 would prohibit financial agreements between brand-name and generic pharmaceutical manufacturers to delay the marketing of lower-cost generic drugs.

14 Sep 2010

Emergency physicians to present research studies at Research Forum 2010

The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.

14 Sep 2010

U.S. adults support restrictions on e-cigarettes based on potential risks

According to the makers of electronic cigarettes, they are new devices that allow users to inhale nicotine but not the toxins of tobacco cigarettes. Advocates hail e-cigarettes as a possible quit-smoking aid.

14 Sep 2010

NCCN Oncology Policy Summit focuses on off-label use of drugs and biologics

The National Comprehensive Cancer Network (NCCN) announced today that key policy organizations and thought leaders will convene to discuss the critically important subject of the use of drugs and biologics for indications that are supported by evidence and compendia, but that are beyond the indications listed in the FDA label. This invitation-only Policy Summit will be held on December 17, 2010 at the National Press Club in Washington DC.

14 Sep 2010

Notch1 protein impacts childhood leukemia progression: Study

A protein crucial for the immune response appears to be a key player in the progression of a devastating form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). Suppressing the activity of the protein kills the leukemic cells, the study shows, opening a potential avenue to new drugs that could prevent progression of the disease.

14 Sep 2010

BC-CfE study finds links between insite use, addiction treatment and stopping injection drug use

A study led by researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) at St. Paul's Hospital and the University of British Columbia has found that supervised injection facilities such as Vancouver's Insite connect clients with addiction treatment, which in turn resulted in greater likelihood of stopping injection drug use for at least six months.

14 Sep 2010